Drug delivery in intervertebral disc degeneration and osteoarthritis: Selecting the optimal platform for the delivery of disease-modifying agents

Fabio Colella, João Pedro Garcia, Marco Sorbona, Andrea Lolli, Bernardo Antunes, Domenico D'Atri, Florian P.Y. Barré, Jacopo Oieni, Maria Letizia Vainieri, Luana Zerrillo, Serdar Capar, Sonja Häckel, Yunpeng Cai, Laura B. Creemers*

*Corresponding author for this work

Research output: Contribution to journalReview article

Abstract

Osteoarthritis (OA) and intervertebral disc degeneration (IVDD) as major cause of chronic low back pain represent the most common degenerative joint pathologies and are leading causes of pain and disability in adults. Articular cartilage (AC) and intervertebral discs are cartilaginous tissues with a similar biochemical composition and pathophysiological aspects of degeneration. Although treatments directed at reversing these conditions are yet to be developed, many promising disease-modifying drug candidates are currently under investigation. Given the localized nature of these chronic diseases, drug delivery systems have the potential to enhance therapeutic outcomes by providing controlled and targeted release of bioactives, minimizing the number of injections needed and increasing drug concentration in the affected areas. This review provides a comprehensive overview of the currently most promising disease-modifying drugs as well as potential drug delivery systems for OA and IVDD therapy.

Original languageEnglish
Pages (from-to)1-15
Number of pages15
JournalJournal of Controlled Release
Early online date27 Aug 2020
DOIs
Publication statusE-pub ahead of print - 27 Aug 2020

Fingerprint Dive into the research topics of 'Drug delivery in intervertebral disc degeneration and osteoarthritis: Selecting the optimal platform for the delivery of disease-modifying agents'. Together they form a unique fingerprint.

Cite this